A Closer Look at Viking Therapeutics's Options Market Dynamics
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20 ...
Viking Therapeutics completes enrollment in Phase 2 trial of VK2735
Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...
Brokerages Set Viking Therapeutics, Inc. (NASDAQ:VKTX) Target Price at $97.67
Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research ...
Yahoo Finance4d
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
The most recent trading session ended with Viking Therapeutics, Inc. (VKTX) standing at $29.28, reflecting a +1.14% shift from the previouse trading day's closing. The stock's change was less than ...
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Hosted on MSN10d
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...
Morningstar3d
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...
Yahoo Finance12d
Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement
Viking Therapeutics experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 program targeting ...